Clinical and Pathological Features of Small Intestine Tumors
International Journal of Clinical Oncology and Cancer Research
Volume 1, Issue 1, December 2016, Pages: 15-25
Received: Nov. 12, 2016; Accepted: Dec. 17, 2016; Published: Jan. 10, 2017
Views 2854      Downloads 103
Authors
Zheng Wang, Department of General Surgery, Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Guangzhou, China
Shijie Huang, Department of Gastrointestinal Surgery, the 4th Affiliated Hospital of Jinan University, Guangzhou Red Cross Hospital, Guangzhou, China
Jianhua Lin, Department of Hepatobiliary Surgery, Nanfang Hospital Affiliated to Southern Medical University, Guangzhou, China
Yixiong Lin, Department of Hepatobiliary Surgery, Nanfang Hospital Affiliated to Southern Medical University, Guangzhou, China
Jie Zhou, Department of Hepatobiliary Surgery, Nanfang Hospital Affiliated to Southern Medical University, Guangzhou, China
Article Tools
Follow on us
Abstract
Small intestinal tumor is a rare disease, with atypical symptoms, difficult for early diagnosis, with Controversial treatment. This study was to provide reference for prevention, diagnosis and treatment of this tumor. 57 cases of small intestinal tumor were reviewed. Clinicopathological features, survival and prognosis were followed up. Rates were compared using chi-square test, means between multiple groups were compared using ANOVA, OS was analyzed by Kaplan–Meier, COX proportional hazard model was for analyzing the prognosis. Number of cases showed increasing trend since 2000. Female exceeded Male except for jejunum tumor, but without significant difference; There were no significant difference between cases of more and less than 60 years of age. Exept for rare pathological types of carcinoid, female exceeded male, but without significant difference. Abdominal pain was the most common main clinical manifestation. 26.3% patients were found during treatment for intestinal obstruction. Jaundice was the manifestation of duodenal tumors, especially located ampulla of Vater. Anal stopping exhaust defecation was main clinical manifestation of ileal tumors. Main clinical symptom of adenocarcinoma was jaundice. Stromal tumor had clinical manifestations of diarrhea. Abdominal pain was primary clinical manifestation of other extremely rare pathological types. Gastrointestinal endoscopy was the most common examinational procedure. In Conclusions, Adenocarcinoma was the most common type among small intestinal tumors. Age had no effect on the choice of operative or chemotherapy option. Gender or age was independent prognostic factors for OS. Surgery was the most effective treatment, role of chemotherapy displayed no survival benefit.
Keywords
Small Intestinal Tumor, Clinicopathological Features, Treatment, Prognosis
To cite this article
Zheng Wang, Shijie Huang, Jianhua Lin, Yixiong Lin, Jie Zhou, Clinical and Pathological Features of Small Intestine Tumors, International Journal of Clinical Oncology and Cancer Research. Vol. 1, No. 1, 2016, pp. 15-25. doi: 10.11648/j.ijcocr.20160101.13
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Wu JH, Miao S, Hou LH, Jia YL.. Surgical treatment and prognostic factors of primary small intestine tumors. Med J Chin PAP 2016; 27: 143-5.
[2]
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
[3]
Caruso S, Marrelli D, Pedrazzani C, Neri A, Mazzei MA, Onorati M, et al. A rare case of primary small bowel adenocarcinoma with intussusception. Tumori 2010; 96: 355-7.
[4]
Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents Vol. IX. IARC Scientific Publication No. 160. Lyon: IARC; 2007.
[5]
Kim CH, Kye BH, Lee JI, Kim SH, Kim HJ, Kang WK, et al. Clinicopathological features of primary jejunoileal tumors. J Korean Soc Coloproctol 2010; 26: 334-8.
[6]
Overman MJ. Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res 2009; 3: 90–6.
[7]
Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers Prev 1988; 7: 243-51.
[8]
Sanders LM, Henderson CE, Hong MY, Barhoumi R, Burghardt RC, Carroll RJ, et al. Pro-oxidant environment of the colon compared to the small intestine may contribute to greater cancer susceptibility. Cancer Lett 2004; 208 (2): 155–61.
[9]
Fletcher CD, Beman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65.
[10]
Liu T, Zhang BL, He XL, Tong Z, Zhu LW, Wang PZ. Clinicopathological analysis of primary small intestinal neoplasm in 111 cases. Chin J Gastrointest Surg 2002; 5: 259-62.
[11]
Chang HK, Yu E, Kim J, Bae YK, Jang KT, Jung ES, et al; Korean Small Intestinal Cancer Study Group. Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases.Hum Pathol 2010; 41: 1087-96.
[12]
Lambert P, Minghini A, Pincus W, Kolm P, Perry RR. Treatment and prognosis of primary malignant small bowel tumor. Am Surg 1996; 62: 709-15.
[13]
Wang YB, Qi DD, Li J. Clinical analysis of 116 cases of primary small intestinal tumors. J REG ANAT OPER SURG 2013; 22: 429-30.
[14]
Lou HJ, Ning SB, Tang J, Zhu M, Jin XW, Mao GP. Clinical characteristics and diagnosis and treatment analysis of primary small intestinal tumor. Medical Journal of Air Force 2015; 31: 99-101.
[15]
Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol) 2007; 19: 143-9.
[16]
Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Annals of Surgery 2009; 249: 63-71.
[17]
Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Annals of Oncology 2010; 21: 1786-93.
[18]
Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, et al. Phase II study of capecitabineand oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. Journal of Clinical Oncology 2009; 27: 2598-603.
[19]
Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004; 101: 518-26.
[20]
Howe JR, Karnell LH, Menck HR, Scott-Conner C. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer 1999; 86: 2693-706.
[21]
Overman MJ, Hu CY, Wolff RA, Chang GJ. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 2010; 116: 5374-82.
[22]
Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. The American Journal of Surgery 2010; 199: 797–803.
[23]
Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 2010; 49: 474-9.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186